Vertex Pharmaceuticals Phase 2 Results of VX-147
Vertex Pharmaceuticals (VRTX) announced today that, in a Phase 2 proof-of-concept (POC) study in patients with APOL1-mediated focal segmental glomerulosclerosis (FSGS), VX-147, on top of standard of care, achieved a statistically significant, substantial and clinically meaningful . . .
This content is for paid subscribers.
Today’s Highlights December 1, 2021